Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for
the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In …

IL-2 was first identified as a growth factor capable of driving the expansion of activated
human T cell populations. In the more than 40 years since its discovery, a tremendous …

BACKGROUND A previous phase I study showed that the infusion of autologous Tregs
expanded ex vivo into patients with recent-onset type 1 diabetes (T1D) had an excellent …

Regulatory T (Treg) cells suppress inflammation and regulate immune system activity. In
patients with systemic or organ-specific autoimmune diseases or those receiving …

Depletion of regulatory T (TReg) cells in otherwise healthy individuals leads to multi-organ
autoimmune disease and inflammation. This indicates that in a normal immune system …

Type 1 diabetes (T1D) results from destruction of pancreatic beta cells by T cells of the
immune system. Despite improvements in insulin analogs and continuous blood glucose …

Regulatory T cells (Treg) are crucial for the maintenance of peripheral tolerance and for the
control of ongoing inflammation and autoimmunity. The cytokine interleukin-2 (IL-2) is …

Recent studies highlight the implication of innate and adaptive immunity in the
pathophysiology of Alzheimer's disease, and foster immunotherapy as a promising strategy …

Background Patients with vasculitis induced by the hepatitis C virus (HCV) have reduced
levels of regulatory T cells (Tregs). Resolution of HCV infection correlates with cure of …

Treatments that block tumour necrosis factor (TNF) have major beneficial effects in several
autoimmune and rheumatic diseases, including rheumatoid arthritis. However, some …